The largest blog for reading the latest medical research on all disease, the prevention and its treatment . Pulled from variety of sources

Wednesday, September 7, 2016

The pill has driven down ovarian cancer death rates worldwide : rawstory





according to rawstory

The pill has driven down ovarian cancer death rates worldwide

The pill has driven down ovarian cancer death rates worldwide
The pill has driven down ovarian cancer death rates worldwide
The birth control pill has not only granted women greater reproductive freedom, it may have also protected them against dying from ovarian cancer, suggests a new study published Tuesday in the Annals of Oncology.Researchers analyzed trends in ovarian cancer death rates across more than 30 different countries, including the United States, between 1970 to 2012.…


moreover from foxnews

New drugs for ovarian cancer

New drugs for ovarian cancer
New drugs for ovarian cancer
A new class of drugs could be a significant step forward in the treatment of ovarian cancer, one of the most lethal forms of the disease.The drugs, known as PARP inhibitors, are thought to help the body slow the disease's progression by helping to prevent cancer cells from repairing themselves after chemotherapy treatment, thereby shrinking tumors and delaying relapses.The drugs don't work in everyone, and are thought to have the greatest effect in women with mutations of the BRCA genes, who represent about 15 percent of ovarian-cancer patients.But recent research, still ongoing, indicates that the drugs may benefit an additional 35 percent of patients with different genetic profiles.


as well pharmacist

New drugs for ovarian cancer patients

New drugs for ovarian cancer patients
New drugs for ovarian cancer patients
A new class of drugs, known as PARP inhibitors, could be a significant step forward in the treatment of ovarian cancer.The drugs are thought to help the body slow the disease's progression by helping to prevent cancer cells from repairing themselves after chemotherapy treatment, thereby shrinking tumors and delaying relapses.The drugs do not work in everyone, and are thought to have the greatest effect in women with mutations of the BRCA genes, who represent about 15% of ovarian-cancer patients.But recent research indicates that the drugs may benefit an additional 35% of patients with different genetic profiles.


No comments:

Post a Comment